Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06254950




Registration number
NCT06254950
Ethics application status
Date submitted
2/02/2024
Date registered
12/02/2024
Date last updated
26/09/2024

Titles & IDs
Public title
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Scientific title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
2023-506769-67
Secondary ID [2] 0 0
TAK-279-UC-2001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TAK-279
Treatment: Drugs - Placebo

Experimental: TAK-279 Dose 1 - TAK-279, capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.

Experimental: TAK-279 Dose 2 - TAK-279, capsules, orally at Dose 2 for 12 weeks followed by TAK-279 capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.

Placebo comparator: Placebo - TAK-279 matching placebo capsules, orally, for 12 weeks followed by TAK-279 capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.


Treatment: Drugs: TAK-279
TAK-279 capsules.

Treatment: Drugs: Placebo
TAK-279 placebo-matching capsules.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS)
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Percentage of Participants Achieving Clinical Response at Week 12 Based on Modified Mayo Score (mMS)
Timepoint [1] 0 0
Baseline, Week 12
Secondary outcome [2] 0 0
Percentage of Participants Achieving Symptomatic Remission at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Percentage of Participants Achieving Endoscopic Improvement at Week 12
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Percentage of Participants Achieving Endoscopic Remission at Week 12
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
Percentage of Participants With no Bowel Urgency at Week 12
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Percentage of Participants With no Abdominal Pain at Week 12
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score =170 at Week 12
Timepoint [7] 0 0
Week 12
Secondary outcome [8] 0 0
Change From Baseline in Disease-Specific Health-related Quality of Life (HRQoL) as Measured by IBDQ Total Score at Week 12
Timepoint [8] 0 0
Baseline and Week 12
Secondary outcome [9] 0 0
Change From Baseline in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12
Timepoint [9] 0 0
Baseline and Week 12

Eligibility
Key inclusion criteria
1. Male or female aged 18-75 years old with diagnosis of UC for at least 30 days. In South Korea, the age requirement for adult participants is =19 years of age.
2. Confirmed diagnosis of moderately to severely active UC assessed by mMS and ES.
3. Participants with a history of inadequate response to, loss of response to, or intolerance to one or more of conventional, biologic or advance therapies for UC.
4. Participants must meet the contraception recommendations.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants with indeterminate/unclassified inflammatory bowel disease (IBD), microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease associated with colitis, and/or clinical/histologic findings suggestive of Crohn's disease (CD).
2. Participants with complications of UC such as strictures, stenoses, fistulas, short gut syndrome, or any other manifestation that might require surgery during the study.
3. Participants with a current ileostomy or colostomy. Participants who had a J-pouch are excluded, as a J-pouch could result in a stoma.
4. Participants who have failed 3 or more classes of advanced therapies.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/03/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
4/08/2027
Actual
Sample size
Target
207
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Nepean Clinical School - Kingswood
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Sydney
Recruitment hospital [3] 0 0
Western Health/Footscray Hospital - Melbourne
Recruitment hospital [4] 0 0
Harry Perkins Medical Research Institute Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2747 - Kingswood
Recruitment postcode(s) [2] 0 0
2139 - Sydney
Recruitment postcode(s) [3] 0 0
3011 - Melbourne
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
Belgium
State/province [14] 0 0
Anderlecht / Region Capitale De Bruxelles/ Brussel
Country [15] 0 0
Belgium
State/province [15] 0 0
Leuven
Country [16] 0 0
Canada
State/province [16] 0 0
Alberta
Country [17] 0 0
Canada
State/province [17] 0 0
British Columbia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Czechia
State/province [20] 0 0
Hradec Kralove
Country [21] 0 0
Czechia
State/province [21] 0 0
Ostrava-Poruba
Country [22] 0 0
Czechia
State/province [22] 0 0
Praha 5
Country [23] 0 0
Denmark
State/province [23] 0 0
Syddanmark
Country [24] 0 0
Denmark
State/province [24] 0 0
Aalborg
Country [25] 0 0
Denmark
State/province [25] 0 0
Esbjerg
Country [26] 0 0
Denmark
State/province [26] 0 0
Hillerod
Country [27] 0 0
Denmark
State/province [27] 0 0
Hvidovre
Country [28] 0 0
Denmark
State/province [28] 0 0
Koge
Country [29] 0 0
France
State/province [29] 0 0
Chambray-les-Tours
Country [30] 0 0
France
State/province [30] 0 0
Clermont-Ferrand
Country [31] 0 0
France
State/province [31] 0 0
Nice Cedex 3
Country [32] 0 0
France
State/province [32] 0 0
Saint Etienne
Country [33] 0 0
France
State/province [33] 0 0
Vandoeuvre les Nancy
Country [34] 0 0
Germany
State/province [34] 0 0
Frankfurt Am Main
Country [35] 0 0
Germany
State/province [35] 0 0
Hamburg
Country [36] 0 0
Germany
State/province [36] 0 0
Hannover
Country [37] 0 0
Germany
State/province [37] 0 0
Heidelberg
Country [38] 0 0
Germany
State/province [38] 0 0
Kiel
Country [39] 0 0
Germany
State/province [39] 0 0
Ludwigshafen
Country [40] 0 0
Germany
State/province [40] 0 0
Mannheim
Country [41] 0 0
Germany
State/province [41] 0 0
Tuebingen
Country [42] 0 0
Germany
State/province [42] 0 0
Ulm
Country [43] 0 0
Greece
State/province [43] 0 0
Achaia
Country [44] 0 0
Greece
State/province [44] 0 0
Attiki
Country [45] 0 0
Greece
State/province [45] 0 0
Crete
Country [46] 0 0
Greece
State/province [46] 0 0
Athens
Country [47] 0 0
Hungary
State/province [47] 0 0
Budapest
Country [48] 0 0
Hungary
State/province [48] 0 0
Vac
Country [49] 0 0
Italy
State/province [49] 0 0
Bologna
Country [50] 0 0
Italy
State/province [50] 0 0
Milan
Country [51] 0 0
Italy
State/province [51] 0 0
Palermo
Country [52] 0 0
Italy
State/province [52] 0 0
Rome
Country [53] 0 0
Italy
State/province [53] 0 0
Rozzano
Country [54] 0 0
Italy
State/province [54] 0 0
Torino
Country [55] 0 0
Japan
State/province [55] 0 0
Chiba
Country [56] 0 0
Japan
State/province [56] 0 0
Hokkaido
Country [57] 0 0
Japan
State/province [57] 0 0
Osaka
Country [58] 0 0
Japan
State/province [58] 0 0
Tokyo
Country [59] 0 0
Japan
State/province [59] 0 0
Fukuoka
Country [60] 0 0
Japan
State/province [60] 0 0
Saga
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Gangwon
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Busan
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Daegu
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Seoul
Country [65] 0 0
Netherlands
State/province [65] 0 0
Tilburg
Country [66] 0 0
Norway
State/province [66] 0 0
Akershus
Country [67] 0 0
Norway
State/province [67] 0 0
Gjettum
Country [68] 0 0
Norway
State/province [68] 0 0
Oslo
Country [69] 0 0
Poland
State/province [69] 0 0
Dolnolskie
Country [70] 0 0
Poland
State/province [70] 0 0
Dolnoslaskie
Country [71] 0 0
Poland
State/province [71] 0 0
Kujawsko-pomorskie
Country [72] 0 0
Poland
State/province [72] 0 0
Kujawsko-pomo
Country [73] 0 0
Poland
State/province [73] 0 0
Lodzkie
Country [74] 0 0
Poland
State/province [74] 0 0
Mazowieckie
Country [75] 0 0
Poland
State/province [75] 0 0
Pomorskie
Country [76] 0 0
Poland
State/province [76] 0 0
Zachodniopomorskie
Country [77] 0 0
Poland
State/province [77] 0 0
Lodz
Country [78] 0 0
Poland
State/province [78] 0 0
Lublin
Country [79] 0 0
Poland
State/province [79] 0 0
Rzeszow
Country [80] 0 0
Poland
State/province [80] 0 0
Tychy
Country [81] 0 0
Poland
State/province [81] 0 0
Warsaw
Country [82] 0 0
Poland
State/province [82] 0 0
Wroclaw
Country [83] 0 0
Poland
State/province [83] 0 0
Zamosc
Country [84] 0 0
Romania
State/province [84] 0 0
Jud Timis
Country [85] 0 0
Romania
State/province [85] 0 0
Bucharest
Country [86] 0 0
Romania
State/province [86] 0 0
Bucuresti
Country [87] 0 0
Slovakia
State/province [87] 0 0
Banska Bystrica
Country [88] 0 0
Slovakia
State/province [88] 0 0
Bratislava
Country [89] 0 0
Slovakia
State/province [89] 0 0
Kosice
Country [90] 0 0
Slovakia
State/province [90] 0 0
Nove Zamky
Country [91] 0 0
Spain
State/province [91] 0 0
Fuenlabrada
Country [92] 0 0
Spain
State/province [92] 0 0
Huelva
Country [93] 0 0
Spain
State/province [93] 0 0
Madrid
Country [94] 0 0
Switzerland
State/province [94] 0 0
Basel
Country [95] 0 0
Taiwan
State/province [95] 0 0
Changhua County
Country [96] 0 0
Taiwan
State/province [96] 0 0
Zhongzheng District
Country [97] 0 0
Taiwan
State/province [97] 0 0
Kaohsiung
Country [98] 0 0
Taiwan
State/province [98] 0 0
Taichung City
Country [99] 0 0
Taiwan
State/province [99] 0 0
Taoyuan City
Country [100] 0 0
United Kingdom
State/province [100] 0 0
E1 2at
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Greater London
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Belfast
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Cambridge
Country [104] 0 0
United Kingdom
State/province [104] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems.

The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks).

During the study, participants will visit their study clinic several times.
Trial website
https://clinicaltrials.gov/study/NCT06254950
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Takeda Contact
Address 0 0
Country 0 0
Phone 0 0
+1-877-825-3327
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06254950